Journal Article Ppublish 1 citation
PubMed: 41377165 DOI: 10.36922/jctr025260029
Association between serum uric acid and prostate cancer risk: The modifying role of CTGF genotype.
J Clin Transl Res 11(5):96-105
Authors: Randi Chen, Timothy A Donlon, Richard C Allsopp, Brian J Morris, Bradley J Willcox, Kamal H Masaki
Affiliations
- Department of Research, Kuakini Japan-Hawaii Cancer Study, Kuakini Honolulu Heart Program, Center of Biomedical Research Excellence (COBRE) for Clinical and Translational Research on Aging, Kuakini Medical Center, Honolulu, Hawaii, United States of America.
- Department of Cell and Molecular Biology, University of Hawaii, Honolulu, Hawaii, United States of America.
- Department of Anatomy, Biochemistry and Physiology, Institute for Biogenesis Research, University of Hawaii, Honolulu, Hawaii, United States of America.
- School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.
- Department of Geriatric Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
Abstract
BACKGROUND
The role of uric acid in prostate cancer risk remains uncertain, with evidence suggesting both carcinogenic and protective effects. Genetic factors may be key modifiers of this association.
OBJECTIVE
This study aimed to determine whether the relationship between uric acid and prostate cancer risk differs by the rs9399005 genotype of connective tissue growth factor (CTGF).
METHODS
We examined 6,259 Japanese-American men in Hawaii, cancer-free at baseline (1965-1968, ages 45-68), who were followed for incident prostate cancer until 1999. Hyperuricemia was defined as serum uric acid ≥7.0 mg/dL. CTGF genotypes were classified as common allele homozygotes (CC) or minor allele carriers (T). Cox proportional hazards models estimated hazard ratios (HRs), adjusting for age and potential confounders.
RESULTS
During a median follow-up of 29.7 years, 285 prostate cancer cases were identified. A significant interaction between CTGF and hyperuricemia was observed. Among men with the CTGF-T genotype, hyperuricemia was not associated with risk (HR = 0.77, 95% confidence interval [CI]: 0.51-1.17). In contrast, among CTGF-CC homozygotes, hyperuricemia was linked to a higher risk (HR = 1.91, 95% CI: 1.21-2.99). Men with both the CTGF-CC genotype and hyperuricemia had a higher risk (HR = 1.72, 95% CI: 1.17-2.54) compared with all other subjects.
CONCLUSION
The association between uric acid and prostate cancer varied by CTGF genotype. Hyperuricemia increased risk among CTGF-CC homozygotes, whereas a nonsignificant protective effect was seen among T allele carriers.
RELEVANCE TO PATIENTS
Monitoring and lowering serum uric acid may help reduce prostate cancer risk in men with the CTGF-CC genotype.
MeSH
Hyperuricemia, Uric Acid, Serum, Homozygote, Neoplasms, Prostate, Prostatic Neoplasms, Alleles, Genotype